Stock Events

Stock Events

Galderma Group 

€171
0
+€4+2.4% Today

Statistics

Day High
171
Day Low
170
52W High
180
52W Low
149
Volume
0
Avg. Volume
17
Mkt Cap
0
P/E Ratio
-
Dividend Yield
0.04%
Dividend
0.07

Upcoming

24
APR
Dividend Ex
Increased
 
27
APR
Dividend Ex
Estimated
 
28
APR
Dividend Payment
Increased
 
1
MAY
Dividend Payment
Estimated
 
26
APR 27
Dividend Ex
Estimated
 

Dividends

0.04%Dividend Yield
May 26
€0.07
Apr 26
€0.38
Apr 25
€0.07
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5MarExpected
Q2 2025
Q4 2025
0.99
1.24
1.49
1.74
Expected EPS
1.35439425
Actual EPS
1.7441324999999999

Financials

11.78%Profit Margin
Profitable
2023
2024
2025
8.87BRevenue
1.04BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GALD.VI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson offers a wide range of skincare products through its consumer health division, directly competing with Galderma's offerings in the dermatological care market.
Novartis
NVS
Mkt Cap297.32B
Novartis, former parent company of Galderma, has a strong presence in the healthcare sector, including dermatology, competing in therapeutic areas similar to Galderma.
Pfizer
PFE
Mkt Cap161.09B
Pfizer competes in the pharmaceuticals sector including dermatology, offering products that overlap with Galderma’s therapeutic solutions.
Merck
MRK
Mkt Cap298.84B
Merck operates in the healthcare and pharmaceutical sectors with products that compete in dermatological conditions, a key area for Galderma.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb competes in various therapeutic areas including those that overlap with Galderma’s dermatology-focused portfolio.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly competes in the pharmaceutical field with a focus on medical dermatology, offering treatments that can compete with Galderma’s products.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline has a diversified healthcare portfolio that includes skin health products, competing with Galderma in the dermatology market.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca operates broadly in the pharmaceutical sector, including areas that compete with Galderma’s dermatological treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals focuses on innovative treatments, including for skin diseases, which puts it in competition with Galderma’s dermatology products.

About

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Show more...
CEO
Dr. Flemming Ornskov M.B.A., M.D., M.P.H.
Employees
7676
Country
CH
ISIN
CH1335392721

Listings

MX
MX
GALDN.MX
F
DE
PY3.F
MI
IT
1GALD.MI
VI
AT
GALD.VI

0 Comments

Share your thoughts

FAQ

What is Galderma Group stock price today?▼
The current price of GALD.VI is €171 EUR — it has increased by +2.4% in the past 24 hours. Watch Galderma Group stock price performance more closely on the chart.
What is Galderma Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galderma Group stocks are traded under the ticker GALD.VI.
When is the next Galderma Group earnings date?▼
Galderma Group is going to release the next earnings report on July 23, 2026.
What were Galderma Group earnings last quarter?▼
GALD.VI earnings for the last quarter are 1.74 EUR per share, whereas the estimation was 1.35 EUR resulting in a +28.78% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Galderma Group revenue for the last year?▼
Galderma Group revenue for the last year amounts to 8.87B EUR.
What is Galderma Group net income for the last year?▼
GALD.VI net income for the last year is 1.04B EUR.
Does Galderma Group pay dividends?▼
Yes, GALD.VI dividends are paid annual. The last dividend per share was 0.07 EUR. As of today, Dividend Yield (FWD)% is 0.04%.
How many employees does Galderma Group have?▼
As of April 08, 2026, the company has 7,676 employees.
When did Galderma Group complete a stock split?▼
Galderma Group has not had any recent stock splits.
Where is Galderma Group headquartered?▼
Galderma Group is headquartered in Zug, CH.